Scientific Sessions 2025  /  Innovations and Challenges in Preclinical Studies of Group 2 and Group 3 PH  /  Molecular Determinants of Vascular Remodeling in Group 3 PH
Logo

American Heart Association

  70
  0

Final ID:

Molecular Determinants of Vascular Remodeling in Group 3 PH

  • Karmouty-quintana, Harry  ( UNIVERSITY OF TEXAS MEDICAL SC , Houston , Texas , United States )
  • Eghbali, Mansoureh  ( UCLA , Los Angeles , California , United States )
  • Ruffenach, Gregoire  ( Université Paris-Saclay , Orsay , France )
    • Author Disclosures:
    Harry Karmouty-Quintana: DO NOT have relevant financial relationships | Mansoureh Eghbali: DO NOT have relevant financial relationships | Gregoire Ruffenach: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Innovations and Challenges in Preclinical Studies of Group 2 and Group 3 PH

Monday, 11/10/2025 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Heterogeneity Among Preclinical Models of Group 2 or Group 3 PH: Myth or Reality?

Lai Yen Chun, Shimoda Larissa, Goncharova Elena

Finding Drugs to Repurpose for Groups 2 and 3 PH: Is There Hope?

Spiekerkoetter Edda, Toshner Mark, Prins Kurt

More abstracts from these authors:
Intralipid confers cardioprotection against ischemia-reperfusion injury via downregulation of NDRG1 expression

Dehghanitafti Ateyeh, Medzikovic Lejla, Ruffenach Gregoire, Hong Jason, Li Min, Sun Wasila, Hatamnejad Mohammad Reza, Eghbali Mansoureh

Comprehensive Single-Cell Atlas of the Human Lung in Pulmonary Arterial Hypertension

Hong Jason, Wong Brenda, Brownstein Adam, Graves Tammy, Aldred Micheala, Dai Zhiyu, Yang Xia, Eghbali Mansoureh

You have to be authorized to contact abstract author. Please, Login
Not Available